Topotecan. A review of its efficacy in small cell lung cancer

Drugs

Volumn 58, Issue 3, 1999, Pages 533-551

  Ormrod, Douglas ^a   Spencer, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BLEOMYCIN; CAMPTOTHECIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN; VINCRISTINE;

ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CROSS RESISTANCE; DRUG ABSORPTION; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG COMBINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG SMALL CELL CANCER; NEUTROPENIA; ORAL DRUG ADMINISTRATION; REVIEW; THROMBOCYTOPENIA; TUMOR VASCULARIZATION;

EID: 0032886996     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199958030-00020     Document Type: Review

References (83)

1. Clark R, Ihde DC. Small-cell lung cancer: treatment progress and prospects. Oncology Huntingt 1998 May; 12: 647-58
2. Landis SH, Murray T, Holden S, et al. Cancer statistics, 1998. CA Cancer J Clin 1998 Jan/Feb; 48 (1): 6-29
3. Ettinger DS. New drugs for treating small cell lung cancer. Lung Cancer 1995 Jun; 12 Suppl. 3: S53-61
4. Rajkumar SV, Adjei AA. A review of the pharmacology and clinical activity of new chemotherapeutic agents in lung cancer. Cancer Treat Rev 1998; 24: 35-53
5. Schiller JH. Topotecan in small cell lung cancer. Semin Oncol 1997 Dec; 24 (6) Suppl. 20: S20-27-S20-33
6. Will ME, Wani MC, Cook CE, et al. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloid leukemia and tumor inhibitor from Camptotheca acununiata. J Am Chem Soc 1966; 88: 3888-90
7. Muggia FM, Creaven PJ, Hansen HH, et al. Phase I clinical trial of weekly and daily treatment with camptothecin (NSC 100880):correlation with preclinical studies. Cancer Chemother Rep 1972; 56(Pt 1): 515-21
8. Moertel CG, Schutt AJ, Reitemeier RG, et al. Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1972; 56(Pt I): 95-101
9. Creaven PJ, Allen LM, Muggia FM. Plasma camptothecin (NSC-100880) levels during a 5-day course of treatment: relation to dose and toxicity. Cancer Chemother Rep 1972; 56(Pt 1): 573-8
10. Hsiang Y-H, Hertzberg R, Hech S, et al. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985; 260 (27): 14873-8
11. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev 1994 Jan; 20: 73-96
12. Rothenberg ML. Topoisomerase I inhibitors:review and update. Ann Oncol 1997; 8: 837-55
13. Hsiang Y-H, Liu LF. Identification of mamallian DNA topoisomerase I as the intracellular target of the anticancer drug camphtothecin. Cancer Res 1988; 48: 1722-6
14. Sinha BK. Topoisomerase inhibitors: a review of their therapeutic potential in cancer. Drugs 1995 Jan; 49: 11-9
15. Burris HA III, Hanauske A-R, Johnson RK, et al. Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro. J Natl Cancer Inst 1992; 84 (23): 1816-20
16. Mitsui I, Kumazawa H, Hirota Y, et al. A new water-soluble camptothecin derivative, DX-89511, exhibits potent antitumor activity against human tumors in vitro and in vivo. Jpn J Cancer Res 1995 Aug; 86: 776-82
17. Houghton PJ, Cheshire PJ, Haltman II JD, et al. Efficacy of topoisomerase 1 inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice hearing xenografts of human tumors. Cancer Chemother Pharmacol 1995 Sep; 36: 393-403
18. Jonsson E, Fridborg H, Csóka K, et al. Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients. Br J Cancer 1997; 76 (2): 211-9
19. Brogden R, Wiseman LR. Topotecan: a review of its potential in advanced ovarian cancer. Drugs 1988 Oct; 56 (4): 709-23
20. Sorensen M, Sehested M, Jensen PB. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan. Br J Cancer 1995 Aug; 72: 399-404
21. Marchesini R, Colombo A, Caserini C, et al. Interaction of ionizing radiation with topotecan in two human tumor cell lines. Int J Cancer 1996; 66 (3): 342-6
22. Hendricks CB, Rowinsky EK, Grochow LB, et al. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res 1992 Apr 15; 52: 2268-78
23. Ma J, Malicpaard M, Nooter K, et al. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br J Cancer 1998; 77 (10): 1645-52
24. Mattern MR, Hofmann GA, Polsky RM, et al. In vitro and in vivo effects of clinically important camptothecin analogues on multidrug-resistant cells. Oncol Res 1993; 5 (12): 467-74
25. van Warmerdam LJC, Verweij J, Schellens JHM, et al. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks. Cancer Chemother Pharmacol 1995 Jan; 35: 237-45
26. Jensen PB, Holm B, Sorensen M, et al. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabin. Br J Cancer 1997; 75 (6): 869-77
27. O'Leary JJ, Shapini RL, Ren CJ, et al. Antiangiogenic effects of camptothecin analogues 9-amino-20(S)-camptothecin, topotecan, and CPT-11 studied in the mouse cornea model. Clin Cancer Res 1999; 5: 181-7
28. Herben VMM, ten Bokkel Huinink WW, Beijnen JH. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996 Aug; 31: 85-102
29. Underberg WJ, Goossen RMJ, Smith BR, et al. Equilibrium kinetics of the new experimental anti-tumour compound SK&F 104864-A in aqueous solution. J Pharm Biomed Anal 1990; 8: 681-3
30. Kuhn J, Irvin R, Kane B, et al. Pharmacokinetics of topotecan following a 30 min infusion or 3 day continuous infusion [abstract]. Pharmacotherapy 1992; 12 (3): 247
31. Blaney SM, Balis FM, Cole DE, et al. Pediatric phase I trial and pharmaeokinetic study of topotecan administered as a 24-hour continuous infusion. Cancer Res 1993 Mar 1; 53: 1032-6
32. van Warmererdam LJC, Creemers G-J, Rodenhuis S, et al. Pharmacokinetics and pharmacodynamics of topotecan administered at a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure. Cancer Chemother Pharmacol 1996: 254-60
33. Grochow LB, Rowinsky EK, Johnson R, et al. Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer. Drug Metab Dispos 1992 Sep-Oct; 20: 706-13
34. Kaye SB, Workman P, Graham MA, et al. Pharmacokinetics and early clinical studies of selected new drugs. Cancer Surv 1993; 17: 371-96
35. Schellens JH, Creemers GJ, Beijnen JH, et al. Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor. Br J Cancer 1996 May; 73 (10): 1268-71
36. Kuhn J, Rizzo J, Eckardt J, et al. Phase I bioavailability study of oral topotecan [abstract]. Proc Am Soc Clin Oncol 1995 Mar; 14: 474
37. Davies BE, Minthorn EA, Dennis MJ, et al. The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog. Pharmacol Res 1997; 14 (10) Get: 1461-5
38. Gerrits CJH, Schellens JHM, Burris H, et al. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin). Clin Cancer Res 1999 Jan; 5: 69-75
39. Zamboni WC, Bowman LC, Tan M, et al. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors. Cancer Chemother Pharmacol 1999 Jun; 43, 450-560
40. Wall JG, Burris III HA, von Hoff DD, et al. A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 10864) given as an intravenous bolus every 21 days. Anticancer Drugs 1992 Aug; 3: 337-45
41. Lilenbaum RC, Ratain MJ, Miller AA, et al. Phase I study of paelitaxel and topotecan in patients with advanced tumors: a Cancer and Leukemia Group B Study. J Clin Oncol 1995 Sep; 13: 2230-7
42. Gizawy EL, Hedaya MA. Comparative brain tissue distribution of camptothecin and topotecan in the rat. Cancer Chemother Pharmacol 1999; 43 (5): 364-70
43. Blaney SM, Phillips PC, Packer RJ, et al. Phase II evaluation of topotecan for pediatric central nervous system tumors. Cancer 1996; 78 (3); 527-31
44. Miller AB, Hoogstraten B, Staquet M, et al. Reporting the results of cancer treatment. Cancer 1981 Jan; 47: 207-14
45. Perez-Soler R, Glisson BS, Lee JS, et al. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 1996; 14 (10): 2785-90
46. Eckardt J, Gralla R, Palmer MC, et al. Topotecan (T) as second-line therapy in patients (pts) with small cell lung cancer (SCLC): a phase II study [abstract]. Ann Oncol 1996; 7 Suppl. 5: 107
47. Ardizzoni A, Hansen H, Dombernowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A phase II study in patients with refractory and sensitive disease. J Clin Oncol 1997; 15 (5): 2090-6
48. von Pawel J, Depierre A, Hans K, et al. Topotecan (Hycamtin®) in small cell lung cancer after failure of first line therapy: multicentre phase II study [abstract]. Eur J Cancer A 1997 Sep; 33 Suppl. 8: S229
49. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vineristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999 Feb; 17: 658-67
50. Shepherd FA, Evans WK, MacCormick R, et al. Cyclophosphamide, doxorubicin, and vincristine in etoposide-and cisplatin-resistant small cell lung cancer. Cancer Treat Rep 1987; 71 (10): 941-4
51. Sculier JP, Klastersky L, Libert P, et al. A phase II study evaluating CAVi (cyclophosphamide, adriamycin, vincristine) potentiated or not by amphotericin B entrapped into sonicated liposomes, as salvage therapy for small-cell lung cancer. Lung Cancer 1990; 6: 110-8
52. SmithKline Beecham Pharmaceuticals. Prescribing information. Hycamtin® brand of topotecan hydrochloride for injection (for intravenous use). Philadelphia, USA, 1998
53. Gerrits CJH, Burris H, Schellens JHM, et al. Five days of oral topotecan (Hycamtin), a phase I and pharmacological study in adult patients with solid tumours. Eur J Cancer 1998; 34 (7): 1030-5
54. von Pawel J, Gatzemeier A, Harstrick M, et al. A multicentre randomised phase II study of oral topotecan versus IV topotecan for second line therapy in sensitive patients with small cell lung cancer [abstract]. Proc Am Soc Clin Oncol 1999 May; 18: 471a
55. Hainsworth JD, Burris HA, Morrissey LH, et al. Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer. Cancer 1999; 85 (5): 1179-85
56. Frasci G, Panza N, Comella P, et al. Cisplatin-topotecan-paclitaxel weekly administration with G-CSF support for ovarian and small-cell lung cancer patients: a dose finding study. Ann Oncol 1999; 10 (3): 355-8
57. Ardizzoni A, Manegold C, Gaafar R, et al. Combination chemotherapy with cisplatin and topotecan as second-line treatmem of sensitive (S) and refractoryt (R) small cell lung cancer (SCLC): an EORTC LCCG phase II study [abstract]. Proc Am Soc Clin Oncol 1999 May; 18 (5): 471a
58. Jacobs SA, Jett JR, Belani CP, et al. Toptecan and paclitaxel, an active couplet, in untreated extensive disease small cell lung caneer [abstract]. Proc Am Soc Clin Oncol 1999 May; 18: 470a
59. Tweedy CR, Andrews DF, Ball T. Topotecan and paclitaxel in extensive stage small cell lung cancer as initial therapy [abstract]. Proc Am Soc Clin Oncol 1999; 18: 525a
60. Lynch TJ, Herndon J, Lilenbaum RC, et al. Toxicity of paclitaxel (P) and topotecan (T) in patients with previously intreated extensive small cell lung cancer (E-SCLC) [abstract]. Proc Am Soc Clin Oncol 1999; 18: 515a
61. ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of advanced epithelial ovarian cancer. J Clin Oncol 1997; 15 (6): 2183-93
62. Creemers JG, Bolis G, Gore M, et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. J Clin Oncol 1996 Dec; 14 (12): 3056-61
63. Schiller JH, Kim K, Hutson P, et al. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: an Eastern Cooperative Oncology Group Trial. J Clin Oncol 1996 Aug; 14: 2345-52
64. Emerson DL, Besterman JM, Brown HR, et al. In vivo antitumor activity of two new seven-substituted water-soluble camptothecin analogues. Cancer Res 1995 Feb 1; 55: 603-9
65. O'Reilly S, Rowinsky EK, Slichenmyer W, et al. Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol 1996 Dec; 14 (12): 3062-73
66. O'Reilly SO, Armstrong DK, Grochow LB. Life-threatening myelosuppressinn in patients with occult renal impairment receiving topotecan [letter]. Gynecol Oncol 1997; 67 (3): 329-30
67. O'Reilly S, Rowinski EK, Slichenmyer W, et al. Phase I and pharmacologic studies of topotecan in patients with impaired hepatic function. J Natl Cancer Inst 1996; 88: 817-24
68. Borkowski JM, Duerr M, Donebower RC, et al. Relation between age and clearance rule of nine investigationai anticancer drugs from phase 1 pharmacokinetic data. Cancer Chemother Pharmacol 1994 Mar; 33: 493-6
69. Laub PB, Baker SD, Rowinsky E, et al. Population pharmacokinetic (PK) model for topotecan (TPT) [abstract]. Proc Am Soc Clin Oncol 1998; 17: 186a
70. Ihde DC, Mulshine JL., Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive stage small-cell lung cancer. J Clin Oncol 1994; 12: 2022-34
71. Arriagada R, Le Chevalier T, Borie F, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst 1995; 87 (3): 183-90
72. Sekine I, Nishiwaki Y, Kakinuma R, et al. Late recurrence of small-cell lung cancer: treatment and outcome. Oncology 1996; 53 (4): 318-21
73. Mattern MR, Hofmann GA, McCabe FL, et al. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res 1991 Nov 1; 51: 5813-6
74. Nedle MN, Mehlta M, Krailo M, et al. Phase I study of topotecan as a radiosensitizer prior to daily involved field irradiation in children with intrinsic pontine glioma. A children's cancer group study [abstract]. Proc Am Soc Clin Oncol 1999 May; 18: 558a
75. Berlin JP, Schiller JH, Mehta MP, et al. Phase I study of topotecan and thoracic radiation [abstract]. Proc Am Soc Clin Oncol 1999 May; 18: 175a
76. Rowinsky EK, Kaufmann SH. Topotecan in combination therapy. Semin Oncol 1997 Dec; 24 (6) Suppl. 20: S20. 11-26
77. Saleem A, Ibrahim N, Patel M, et al. Mechanism of resistance in a human cell line exposed to sequential topoisomerase poisoning. Cancer Res 1997; 57 (22): 5100-6
78. Kaufmann SH. Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 1991 Feb 15; 51: 1129-36
79. Bonner JA, Kozelsky TF. The significance of the sequence of administration of topotecan and etoposide. Cancer Chemother Pharmacol 1996; 39: 109-12
80. Tolcher AW, O'Shaughnessy JA, Weiss RB, et al. A phase I study of topotecan followed sequentially by doxorubicin in patients with advanced malignancies. Clin Cancer Res 1997 May; 3: 755-60
81. Hammond LA, Eckardt JR, Ganapathi R, et al. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etopside. Clin Cancer Res 1998 Jun; 4 (6): 1459-67
82. Clark PI, Sutton P, Smith DB, et al. A phase I study of a 5 day schedule of intravenous topotecan (T) and Etoposide (E) in untreated small cell lung cancer (SCLC) [abstract]. Proc Am Soc Clin Oncol 1999; 18: 499a
83. Buchholz H, Manegold C, Drings P, et al. Sequential administration of topotecan (Topo) and etoposide (Eto) in extensive small cell lung cancer - a phase I-study. Proc Am Soc Clin Oncol 1998; 17: 479a